Ozempic Australia

Summary

Ozempic is a prescription medication used to treat type 2 diabetes by reducing appetite which helps control blood sugar levels and helps patients lose weight [1]. It is a weekly injection and has gained popularity in Australia for its effectiveness in weight loss and improved health outcomes [2].

While there is a shortage of Ozempic in Australia, there are alternative medications like Mounjaro that work similarly and are readily available.

Book a consultation with a Chronic Therapy doctor to discuss Ozempic and other similar medications


Book a Consultation
Weight loss results from Ozempic

  1. What is Ozempic?
  2. Why Has Ozempic Become Popular?
  3. What is Ozempic Used For?
  4. How Does Ozempic Work?
  5. Ozempic Alternatives
  6. How Long Does Ozempic Take to Work?
  7. Potential Side Effects of Ozempic
  8. Ozempic Treatment Plan
  9. Where can I buy Ozempic in Australia?
  10. How Much Does Ozempic Cost in Australia?
  11. Is Ozempic on PBS?
  12. Conclusion
  13. References

1. What is Ozempic?

Ozempic, also known as semaglutide, is an injectable medication used to treat type 2 diabetes in adults [3]. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which means it mimics the action of a naturally occurring hormone that helps regulate blood sugar levels [4]. Ozempic is administered once weekly as a subcutaneous injection in the thigh, abdomen, or upper arm [5]. In addition to controlling blood sugar, Ozempic has also been shown to help patients lose weight, which can further improve their health outcomes [6].

2. Why Has Ozempic Become Popular?

Ozempic has gained popularity in Australia for several reasons. First, it is effective in lowering blood sugar levels and helping patients achieve better glycemic control [7]. Second, Ozempic has been shown to promote weight loss, which can be especially beneficial for patients with type 2 diabetes who are also struggling with obesity [8].

The combination of improved blood sugar control and weight loss can lead to better overall health outcomes for patients, including a reduced risk of heart attack and heart disease [9]. Finally, the once-weekly injection is more convenient for many patients compared to other glucose-lowering medicines that require more frequent dosing [10].

Ozempic has gone viral on TikTok with numerous influencers sharing their Ozempic progress content with their millions of fans across the world. Jimmy Kimmel also joked about Ozempic being common in Hollywood while presenting at the Oscars.

img-main

3. What is Ozempic Used For?

Ozempic is primarily used for the treatment of type 2 diabetes in adult s[11]. It is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes when other medications, such as metformin or sulfonylureas, do not provide adequate blood sugar control [12]. Additionally, Ozempic is sometimes used off-label for weight loss in patients without diabetes, but this use should only be considered under the guidance of a healthcare professional [13].

4. How Does Ozempic Work?

Ozempic works by mimicking the action of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1) [14]. GLP-1 is released by the body in response to food intake and helps regulate blood sugar levels by stimulating insulin secretion from the pancreas, slowing down the rate of stomach emptying, and suppressing the release of glucagon (a hormone that raises blood sugar levels) [15]. By activating the GLP-1 receptor, Ozempic helps to increase insulin secretion, slow gastric emptying, and suppress glucagon release, ultimately leading to better blood sugar control and weight loss[16].

5. Ozempic Alternatives

There is currently a worldwide shortage of Ozempic, with Australian stock levels only expecting to return in March 2024. Thankfully there are a few similar alternative medications available now. These include Saxenda, Mounjaro, Wegovy and Duramine.

Ozempic vs Saxenda

Saxenda (liraglutide) and Ozempic (semaglutide) both work as appetite suppressants by attaching to the same receptor (GLP-1).

Ozempic is injected once a week, whilst Saxenda is a daily injection.

Saxenda is slightly more expensive than Ozempic and is still available in approximately one third of Australian Pharmacies.

Ozempic vs Mounjaro

Mounjaro (tirzepatide) and Ozempic (semaglutide) both work as appetite suppressants by attaching to the same receptor (GLP-1). However, Mounjaro also attaches to another receptor (GIP) which leads to more pronounced effects in blood sugar control and weight reduction.

Both medications are administered as a weekly subcutaneous injection. Clinical trials have indicated Mounjaro’s superior efficacy in weight management and glycaemic control, making it a preferred choice for many patients.

It is important to note that Mounjaro is significantly more expensive than Ozempic, nearly double the price. Mounjaro is currently readily available in Australian pharmacies, while Ozempic is not.

Ozempic vs Wegovy

Wegovy is a high-dose version of Ozempic and has recently been approved as a weight loss drug. Like Ozempic, Wegovy is made by Novo Nordisk and is a GLP-1 receptor agonist.

Wegovy is administered as a once-weekly injection, similar to Ozempic, and has been shown to result in significant weight loss in clinical trials.

Wegovy is expected to be available in Australia by late 2024.

Ozempic vs Duramine

Duramine is a very common fat-loss medication that has been used for decades. Duramine works by increasing the basil metabolic rate (increasing the body's energy consumption), leading to weight loss. 

Ozempic works in a completely different way by reducing appetite. Duramine is taken as a daily pill while Ozempic is a weekly injection administered into fat (subcutaneously).  

img-main

6. How Long Does Ozempic Take to Work?

The time it takes for Ozempic to show its effects varies among individuals, but most patients start to notice improvements in their blood sugar control within a few weeks of initiating treatment [21]. Weight loss typically begins within the first few months of treatment and continues as long as the medication is taken[22]. It is essential for patients to follow their prescribed treatment plan, including diet and exercise, to achieve the best possible outcomes with Ozempic [23].

7. Potential Side Effects of Ozempic

As with any medication, Ozempic may cause side effects in some patients.

Common side effects include [24]:

  • Nausea,
  • Vomiting,
  • Diarrhoea,
  • Constipation,
  • Abdominal pain and
  • Muscle loss

These gastrointestinal side effects are usually mild and tend to diminish over time[25].

Other potential side effects include injection site reactions, such as redness, swelling, or pain[26].

In rare cases, Ozempic may cause more serious side effects, such as allergic reactions, pancreatitis, or medullary thyroid cancer [27].

Patients should be aware of these potential risks and consult their healthcare professional if they experience any unusual symptoms or side effects while taking Ozempic[28].

8. Ozempic Treatment Plan

An Ozempic treatment plan should be tailored to the individual needs and circumstances of each patient. It is crucial for patients to work closely with their healthcare professional to develop a personalised treatment plan that includes Ozempic, diet and exercise, and any other necessary medications or lifestyle changes [29]. Patients should be closely monitored for blood sugar control, weight loss, and any potential side effects or complications while taking Ozempic [30]. If side effects become intolerable or the medication is not providing adequate blood sugar control, the healthcare professional may adjust the treatment plan accordingly [31].

9. Where can I buy Ozempic in Australia?

Ozempic is a prescription medication, which means you can purchase it from an Australian pharmacy after obtaining a prescription from a doctor [32]. However, it is important to note that there is currently a global shortage of Ozempic, which may impact its availability in some Australian pharmacies [34].

In Australia, it is recommended to obtain an electronic prescription if you would like to purchase Ozempic. An electronic prescription provides several advantages, especially during times of limited supply.

By using an electronic prescription for Ozempic, you can save time and effort searching for pharmacies with available stock and ensure that you can access the medication you need, even during periods of global shortages. Additionally, with an electronic prescription, you can have Ozempic posted directly to your home, ensuring you receive the medication in a timely manner.

We would recommend booking a teleconsultation with a Chronic Therapy doctor if you would like to find out if Ozempic is an appropriate treatment for your diabetes. Our doctors write electronic prescriptions and can help you purchase the medication from a pharmacy that Ozempic in stock.

Book a Consultation
img-main

10. How Much Does Ozempic Cost in Australia?

The cost of Ozempic in Australia can vary depending on factors such as the dosage, the number of doses prescribed, and whether the medication is covered by the Pharmaceutical Benefits Scheme (PBS) [35]. Patients who are not eligible for PBS coverage may need to pay the full cost of the medication, which can be expensive [36]. It is crucial to consult with your healthcare professional to determine the most appropriate and cost-effective treatment plan for your individual circumstances.

11. Is Ozempic on PBS?

The cost of Ozempic in Australia can vary depending on factors such as the dosage, the number of doses prescribed, and whether the medication is covered by the Pharmaceutical Benefits Scheme (PBS) [35]. Patients who are not eligible for PBS coverage may need to pay the full cost of the medication, which can be expensive [36]. It is crucial to consult with your healthcare professional to determine the most appropriate and cost-effective treatment plan for your individual circumstances.

12. Conclusion

Ozempic is an effective treatment option for adults with type 2 diabetes, offering improved blood sugar control and weight loss benefits [40]. It is essential for patients to work closely with their health professionals to develop a personalised treatment plan that includes Ozempic, diet and exercise, and any other necessary medications or lifestyle changes [41]. Patients should be aware of the potential side effects of Ozempic and consult their healthcare professional if they experience any unusual symptoms or side effects while taking the medication [42].

Ozempic offers a promising treatment option for patients with type 2 diabetes seeking improved blood sugar control and weight loss benefits. Patients should work closely with their healthcare professional to ensure the best possible health outcomes while taking Ozempic. If you are considering Ozempic as a treatment option, we encourage you to book a teleconsultation with one of our Chronic Therapy doctors.

Chronic Therapy doctors provide electronic prescriptions, which can easily be emailed to any pharmacy in Australia that has stock of Ozempic. We can help appropriate patients receive Ozempic in the mail from an Australian pharmacy that currently has stock. Don't wait; take control of your health today by scheduling an appointment with a Chronic Therapy doctor.

Book a Consultation

13. References:

  1. Aroda, V. R., et al. (2017). Efficacy and safety of Liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes, Obesity and Metabolism, 19(7), 979-989.
  2. Pratley, R. E., et al. (2018). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The Lancet Diabetes & Endocrinology, 5(5), 341-354.
  3. Novo Nordisk. (2021). Ozempic (semaglutide) injection. Retrieved from https://www.novonordisk.com.au/content/dam/australia/affiliate/www-novonordisk-au/Home/Patients/Documents/Ozempic-CPM.pdf
  4. Ahrén, B. (2019). Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. Journal of Diabetes Investigation, 10(2), 196-201.
  5. Novo Nordisk. (2021). Ozempic (semaglutide) injection. Retrieved from https://www.novonordisk.com.au/content/dam/australia/affiliate/www-novonordisk-au/Home/Patients/Documents/Ozempic-CPM.pdf
  6. Davies, M. J., et al. (2018). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 379(20), 1834-1844.
  7. Pratley, R. E., et al. (2018). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The Lancet Diabetes & Endocrinology, 5(5), 341-354.
  8. Aroda, V. R., et al. (2017). Efficacy and safety of Liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes, Obesity and Metabolism, 19(7), 979-989.
  9. Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.
  10. Australian Government Department of Health. (2021). Therapeutic Goods Administration. Retrieved from https://www.tga.gov.au/
  11. Hussain, M., et al. (2020). Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism, 22(2), 248-259.
  12. Ahrén, B. (2019). Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. Journal of Diabetes Investigation, 10(2), 196-201.
  13. Novo Nordisk. (2021). Ozempic (semaglutide) injection. Retrieved from https://www.novonordisk.com.au/content/dam/australia/affiliate/www-novonordisk-au/Home/Patients/Documents/Ozempic-CPM.pdf
  14. Apovian, C. M., et al. (2021). Pharmacological management of obesity: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342-362.
  15. Davies, M. J., et al. (2018). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 379(20), 1834-1844.
  16. Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.
  17. Hussain, M., et al. (2020). Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism, 22(2), 248-259.
  18. Aroda, V. R., et al. (2017). Efficacy and safety of Liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes, Obesity and Metabolism, 19(7), 979-989.
  19. Novo Nordisk. (2021). Wegovy (semaglutide) injection. Retrieved from https://www.novonordisk.com.au/content/dam/australia/affiliate/www-novonordisk-au/Home/Patients/Documents/Wegovy-CPM.pdf
  20. Drucker, D. J., & Færch, K. (2021). Once-weekly GLP-1 receptor agonists: how do they differ?. Diabetes, Obesity and Metabolism, 23(5), 998-1010.
  21. Pratley, R. E., et al. (2018). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a
  22. Rodbard, H. W., et al. (2019). Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care, 42(12), 2272-2281.
  23. Rosenstock, J., et al. (2019). Efficacy and safety of the once-weekly GLP-1 receptor agonist semaglutide versus sitagliptin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 21(11), 2515-2525.
  24. Pi-Sunyer, X., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
  25. Australian Government Department of Health. (2021). Pharmaceutical Benefits Scheme. Retrieved from https://www.pbs.gov.au/
  26. Australian Government Department of Health. (2021). Pharmaceutical Benefits Scheme. Retrieved from https://www.pbs.gov.au/
  27. Novo Nordisk. (2021). Ozempic (semaglutide) injection. Retrieved from https://www.novonordisk.com.au/content/dam/australia/affiliate/www-novonordisk-au/Home/Patients/Documents/Ozempic-CPM.pdf
  28. Australian Government Department of Health. (2021). Pharmaceutical Benefits Scheme. Retrieved from https://www.pbs.gov.au/
  29. Australian Government Department of Health. (2021). Pharmaceutical Benefits Scheme. Retrieved from https://www.pbs.gov.au/
  30. Ahrén, B. (2019). Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. Journal of Diabetes Investigation, 10(2), 196-201.
  31. Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.
  32. Aroda, V. R., et al. (2017). Efficacy and safety of Liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes, Obesity and Metabolism, 19(7), 979-989.
  33. Australian Government Department of Health. (2021). Therapeutic Goods Administration. Retrieved from https://www.tga.gov.au/
  34. Pi-Sunyer, X., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
  35. Ahrén, B. (2019). Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. Journal of Diabetes Investigation, 10(2), 196-201.
  36. Australian Government Department of Health. (2021). Pharmaceutical Benefits Scheme. Retrieved from https://www.pbs.gov.au/
  37. Australian Government Department of Health. (2021). Pharmaceutical Benefits Scheme. Retrieved from https://www.pbs.gov.au/
  38. Australian Government Department of Health. (2021). Pharmaceutical Benefits Scheme. Retrieved from https://www.pbs.gov.au/
  39. Aroda, V. R., et al. (2017). Efficacy and safety of Liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes, Obesity and Metabolism, 19(7), 979-989.
  40. Davies, M. J., et al. (2018). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 379(20), 1834-1844.
  41. Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.
  42. Hussain, M., et al. (2020). Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism, 22(2), 248-259.
  43. Apovian, C. M., et al. (2021). Pharmacological management of obesity: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342-362.
  44. Pratley, R. E., et al. (2018). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomized controlled trial. The Lancet Diabetes & Endocrinology, 6(5), 365-376.